The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Open accessAbstract
Suppression of apoptosis by expression of antiapoptotic BCL2 family members is a hallmark of acute myeloblastic leukemia (AML). Induced myeloid leukemia cell differentiation protein (MCL1), an antiapoptotic BCL2 family member, is commonly upregulated in AML cells and is often a primary mode of resistance to treatment with the BCL2 inhibitor venetoclax. Here, we describe VU661013, a novel, potent, selective MCL1 inhibitor that destabilizes BIM/MCL1 association, leads to apoptosis in AML, and is active in venetoclax-resistant cells and patient-derived xenografts. In addition, VU661013 was safely combined with venetoclax for synergy in murine models of AML. Importantly, BH3 profiling of patient samples and drug-sensitivity testing ex vivo accurately predicted cellular responses to selective inhibitors of MCL1 or BCL2 and showed benefit of the combination. Taken together, these data suggest a strategy of rationally using BCL2 and MCL1 inhibitors in sequence or in combination in AML clinical trials. Significance: Targeting antiapoptotic proteins in AML is a key therapeutic strategy, and MCL1 is a critical antiapoptotic oncoprotein. Armed with novel MCL1 inhibitors and the potent BCL2 inhibitor venetoclax, it may be possible to selectively induce apoptosis by combining or thoughtfully sequencing these inhibitors based on a rational evaluation of AML. See related commentary by Leber et al., p. 1511. This article is highlighted in the In This Issue feature, p. 1494
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c
Liu, X., Kim, C. N., Yang, J., Jemmerson, R., & Wang, X. (1996) · Cell · doi:10.1016/s0092-8674(00)80085-9 · Cited by 5,167
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Wei, M. C., Zong, W.-X., Cheng, E. H.-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., & Korsmeyer, S. J. (2001) · Science · doi:10.1126/science.1059108 · Cited by 3,988
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Self-citationbcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Cheng, E. H.-Y. A., Wei, M. C., Weiler, S., Flavell, R. A., Mak, T. W., Lindsten, T., & Korsmeyer, S. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00320-3 · Cited by 1,707
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“Although MCL1 was considered a particularly difficult protein to target with small molecules (45), several groups have recently discovered potent MCL1 inhibitors (46–48).”
BackgroundLetai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476
Self-citationX-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death
Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., Chang, B. S., Thompson, C. B., Wong, S.-L., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467
Self-citationChipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,427
Wang, J.-L., Liu, D., Zhang, Z.-J., Shan, S., Han, X., Srinivasula, S. M., Croce, C. M., Alnemri, E. S., & Huang, Z. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7124 · Cited by 1,201
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Self-citationThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,023
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
Self-citationDiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Del Gaizo Moore, V., Brown, J. R., Certo, M., Love, T. M., Novina, C. D., & Letai, A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 608
Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells
Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S.-I., Akashi, K., & Korsmeyer, S. J. (2005) · Science · doi:10.1126/science.1106114 · Cited by 574
Czabotar, P. E., Westphal, D., Dewson, G., Ma, S., Hockings, C., Fairlie, W. D., Lee, E. F., Yao, S., Robin, A. Y., Smith, B. J., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.031 · Cited by 573
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., & Yuan, J. (2001) · Nature Cell Biology · doi:10.1038/35055085 · Cited by 550
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, S., Kaufman, J. L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., Benboubker, L., Facon, T., Amiot, M., Moreau, P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788786 · Cited by 523
Deng, J., Carlson, N., Takeyama, K., Dal Cin, P., Shipp, M., & Letai, A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.001 · Cited by 513
Structural insights into the degradation of Mcl-1 induced by BH3 domains
Czabotar, P. E., Lee, E. F., van Delft, M. F., Day, C. L., Smith, B. J., Huang, D. C. S., Fairlie, W. D., Hinds, M. G., & Colman, P. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701297104 · Cited by 446
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Structure-guided design of a selective BCL-XL inhibitor
Lessene, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 381
Myeloid cell factor–1 is a critical survival factor for multiple myeloma
Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 367
The Structure of a Bcl-xL/Bim Fragment Complex
Liu, X., Dai, S., Zhu, Y., Marrack, P., & Kappler, J. W. (2003) · Immunity · doi:10.1016/s1074-7613(03)00234-6 · Cited by 357
Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., Komrokji, R., Solomon, S. R., Kolitz, J. E., Cooper, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-540971 · Cited by 339
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
Seymour, J. F., Ma, S., Brander, D. M., Choi, M. Y., Barrientos, J., Davids, M. S., Anderson, M. A., Beaven, A. W., Rosen, S. T., Tam, C. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30012-8 · Cited by 333
Mcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Mcl-1 is essential for the survival of plasma cells
Peperzak, V., Vikström, I., Walker, J., Glaser, S. P., LePage, M., Coquery, C. M., Erickson, L. D., Fairfax, K., Mackay, F., Strasser, A., et al. (2013) · Nature Immunology · doi:10.1038/ni.2527 · Cited by 320
Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V, et al. (2017) · Leukemia · doi:10.1038/leu.2017.63 · Cited by 293
Kvansakul, M., Yang, H., Fairlie, W. D., Czabotar, P. E., Fischer, S. F., Perugini, M. A., Huang, D. C. S., & Colman, P. M. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.83 · Cited by 233
Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based study
Shah, A., Andersson, T. M. ‐., Rachet, B., Björkholm, M., & Lambert, P. C. (2013) · British Journal of Haematology · doi:10.1111/bjh.12425 · Cited by 206
Bogenberger, J. M., Kornblau, S. M., Pierceall, W. E., Lena, R., Chow, D., Shi, C.-X., Mantei, J., Ahmann, G., Gonzales, I. M., Choudhary, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.44 · Cited by 200
Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
Lin, K. H., Winter, P. S., Xie, A., Roth, C., Martz, C. A., Stein, E. M., Anderson, G. R., Tingley, J. P., & Wood, K. C. (2016) · Scientific Reports · doi:10.1038/srep27696 · Cited by 186
Cortes, J. E., Goldberg, S. L., Feldman, E. J., Rizzeri, D. A., Hogge, D. E., Larson, M., Pigneux, A., Recher, C., Schiller, G., Warzocha, K., et al. (2015) · Cancer · doi:10.1002/cncr.28974 · Cited by 175
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh, T.-C., Nguyen, N.-Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., et al. (2018) · Leukemia · doi:10.1038/leu.2017.243 · Cited by 159
Ravandi, F., Ritchie, E. K., Sayar, H., Lancet, J. E., Craig, M., Vey, N., Strickland, S. A., Schiller, G. J., Jabbour, E. J., Erba, H. P., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00201-6 · Cited by 157
Self-citationBogenberger, J. M., Delman, D., Hansen, N., Valdez, R., Fauble, V. D. S., Mesa, R. A., & Tibes, R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.910657 · Cited by 152
Morales, A. A., Kurtoğlu, M., Matulis, S. M., Liu, J., Siefker, D. T., Gutman, D. M., Kaufman, J. L., Lee, K. P., Lonial, S., & Boise, L. (2011) · Blood · doi:10.1182/blood-2011-01-327197 · Cited by 141
Waibel, M., Solomon, V. S., Knight, D. A., Ralli, R., Kim, S., Banks, K.-M., Vidacs, E., Virely, C., Sia, K. C. S., Bracken, L. S., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.038 · Cited by 141
Ryan, J. A., Montero, J., Rocco, J. W., & Letai, A. G. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0107 · Cited by 139
Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy
Lee, J. J., Kong, M., Ayers, G. D., & Lotan, R. (2007) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400701199593 · Cited by 135
Self-citationKeith, F. J., Bradbury, D. A., Zhu, Y., & Russell, N. H. (1995) · PubMed · Cited by 128
Niu, X., Wang, G., Wang, Y., Caldwell, J. T., Edwards, H. J., Xie, C., Taub, J. W., Li, C., Lin, H., & Ge, Y. (2014) · Leukemia · doi:10.1038/leu.2014.72 · Cited by 127
Phillips, D. C., Xiao, Y., Lam, L. T., Litvinovich, E., Roberts-Rapp, L. A., Souers, A. J., & Leverson, J. D. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.88 · Cited by 123
Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells
Wink, G., Ryan, J. A., Gullà, S. V., Letai, A. G., & Keating, A. E. (2014) · ACS Chemical Biology · doi:10.1021/cb500340w · Cited by 121
Jilg, S., Reidel, V., Müller‐Thomas, C., König, J., Schauwecker, J., Höckendorf, U., Huberle, C., Gorka, O., Schmidt, B., Burgkart, R., et al. (2015) · Leukemia · doi:10.1038/leu.2015.179 · Cited by 107
Dey, J., Deckwerth, T. L., Kerwin, W. S., Casalini, J. R., Merrell, A., Grenley, M. O., Burns, C., Ditzler, S. H., Dixon, C., Beirne, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18368-w · Cited by 99
Combined venetoclax and alvocidib in acute myeloid leukemia
Bogenberger, J. M., Whatcott, C. J., Hansen, N., Delman, D., Shi, C.-X., Kim, W., Haws, H., Soh, K. K., Lee, Y. S., Peterson, P. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22284 · Cited by 97
Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold
Zhou, H., Chen, J., Meagher, J. L., Yang, C., Aguilar, A., Liu, L., Bai, L., Cong, X., Cai, Q., Fang, X., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300178u · Cited by 87
Acquired resistance to venetoclax (ABT-199) int(14;18)positive lymphoma cells
Bodo, J., Zhao, X., Durkin, L. M., Souers, A. J., Phillips, D. C., Smith, M. R., & Hsi, E. D. (2016) · Oncotarget · doi:10.18632/oncotarget.12132 · Cited by 69
Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors
Lee, T., Bian, Z., Zhao, B., Hogdal, L. J., Sensintaffar, J., Goodwin, C. M., Belmar, J., Shaw, S., Tarr, J. C., Veerasamy, N., et al. (2016) · FEBS Letters · doi:10.1002/1873-3468.12497 · Cited by 64
Self-citationArellano, M. L., Borthakur, G. M., Berger, M. S., Luer, J., & Raza, A. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.04.007 · Cited by 44
Mcl-1 is vital for neutrophil survival
Murphy, M. P., & Caraher, E. M. (2015) · Immunologic Research · doi:10.1007/s12026-015-8655-z · Cited by 42
Mcl-1 regulates the survival of adult neural precursor cells
Malone, C. D., Hasan, S. M. M., Roome, R. B., Xiong, J., Furlong, M., Opferman, J. T., & Vanderluit, J. L. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.02.003 · Cited by 42
Dynamic BH3 profiling-poking cancer cells with a stick
Montero, J., & Letai, A. G. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1040144 · Cited by 34
Zhou, L., Zhang, Y., Sampath, D., Leverson, J. D., Dai, Y., Kmieciak, M., Nguyen, M. H., Orlowski, R. Z., & Grant, S. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.432 · Cited by 30
Correction: Immunology: Ways around rejection
Vaux, D. L. (1998) · Nature · doi:10.1038/28067 · Cited by 29
The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice
Brinkmann, K., Grabow, S., Hyland, C. D., Teh, C. E., Alexander, W. S., Herold, M. J., & Strasser, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.125 · Cited by 29
Ishizawa, J., Kojima, K., McQueen, T. J., Ruvolo, V. R., Chachad, D., Nogueras‐González, G. M., Huang, X., Pierceall, W. E., Dettman, E. J., Cardone, M. H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138377 · Cited by 26
Zheng, C., Yang, H., Zhang, M., Lu, S., Shi, D., Wang, J., Chen, X., Ren, X., Liu, J., Lv, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.101 · Cited by 25
Grundy, M. A., Seedhouse, C., Jones, T., Elmi, L., Hall, M., Graham, A., Russell, N. H., & Pallis, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190682 · Cited by 20
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Pei, S., Pollyea, D. A., Gustafson, A., Stevens, B. M., Minhajuddin, M., Fu, R., Riemondy, K. A., Gillen, A. E., Sheridan, R. M., Kim, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0710 · Cited by 562
Self-citationThe TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Nechiporuk, T., Kurtz, S. E., Nikolova, O., Liu, T., Jones, C. L., D'Alessandro, A., Culp-Hill, R., d'Almeida, A., Joshi, S. K., Rosenberg, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0125 · Cited by 378
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment
Chen, X., Glytsou, C., Zhou, H., Narang, S., Reyna, D. E., Lopez, A., Sakellaropoulos, T., Gong, Y., Kloetgen, A., Yap, Y. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0117 · Cited by 348
Metadata
- Authors
- Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., Ayers, G. D., Olejniczak, E. T., Fesik, S. W., & Savona, M. R.
- Venue
- Cancer Discovery
- Published
- 2018-12-01
- Volume
- 8
- Issue
- 12
- Pages
- 1566-1581
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2891173371
- Cited by
- 379
- References
- 73
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.